Liraglutide vs Semaglutide
Both are categorized under GLP-1 agonist in our directory—here is how they differ in name, use, and label context.
Both are categorized under GLP-1 agonist in our directory—here is how they differ in name, use, and label context.
PubMed paper counts, ClinicalTrials.gov listings, and regulatory context—aggregated from public databases.
GLP-1 agonist
An earlier daily-injection GLP-1 agonist—still used for diabetes and weight loss.
Liraglutide was the first GLP-1 drug widely used for obesity (Saxenda). It works similarly to semaglutide but requires daily dosing and tends to produce somewhat less weight loss. Well-studied safety profile over many pa…
GLP-1 agonist
A GLP-1 receptor agonist peptide drug approved for type 2 diabetes and chronic weight management.
Semaglutide mimics glucagon-like peptide-1, slowing gastric emptying and increasing satiety. Weekly injection versions (Ozempic, Wegovy) produce significant weight loss in trials. It is a prescription drug—not a supple…
Both are categorized under GLP-1 agonist in our directory—here is how they differ in name, use, and label context. Liraglutide is categorized as GLP-1 agonist; Semaglutide as GLP-1 agonist. Liraglutide: An earlier daily-injection GLP-1 agonist—still used for diabetes and weight loss. Semaglutide: A GLP-1 receptor agonist peptide drug approved for type 2 diabetes and chronic weight management.
No. They are different molecules with distinct names on labels and in research databases. Always match the full INCI or drug name—not a nickname on the front of the package.
Prescription peptide drugs require a clinician and regulated pharmacy supply—they are not cosmetic INCI ingredients or bulk research powders sold like supplements.